Graham Holdings Co. (GHC) - Q1 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. Graham Holdings Company is a diversified holding company with operations in educational services (Kaplan), television broadcasting, manufacturing, healthcare, automotive dealerships, and other businesses. The company is a large accelerated filer.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Operating Revenues | $1,165.9 million | $1,152.7 million |
| Income from Operations | $47.5 million | $35.4 million |
| Net Income (Attributable to GHC) | $23.9 million | $124.4 million |
| Diluted EPS | $5.45 | $27.72 |
| Operating Cash Flow | $46.0 million | $1.1 million |
| Total Debt | $864.6 million | $748.2 million |
| Cash & Cash Equivalents | $156.7 million | $260.9 million |
| Working Capital | $777.0 million | $898.8 million |
Material Changes vs. Prior Period
- Net Income Decline: Net income attributable to common stockholders dropped significantly from $124.4 million to $23.9 million. This was primarily driven by a $66.4 million interest expense charge to adjust the fair value of mandatorily redeemable noncontrolling interests (related to healthcare subsidiary CSI) and a decrease in net gains on marketable equity securities ($43.8 million vs. $104.2 million).
- Revenue Growth: Total revenue increased 1% year-over-year. Growth was led by the Healthcare segment (+36%) and Education segment (+1%), partially offset by declines in Automotive (-8%), Television Broadcasting (-8%), and Manufacturing (-4%).
- Operating Income Improvement: Operating income rose 34% to $47.5 million, driven by improved results in Education, Manufacturing, and Healthcare, despite declines in other segments.
- Debt and Liquidity: Total debt increased by $116.4 million due to net borrowings under the revolving credit facility. Cash and cash equivalents decreased by $104.2 million, largely due to the $186.25 million cash settlement of noncontrolling interests.
Guidance, Outlook, and Risks
- Capital Expenditures: Management estimates 2025 capital expenditures will range between $85 million and $95 million.
- Dividends: The company expects to pay a dividend of $7.20 per share in 2025. The quarterly dividend rate for Q1 2025 was $1.80 per share.
- Outlook: Management believes the company has sufficient financial resources to meet business requirements for the next 12 months. Credit ratings remain Stable (Moody's Ba1, S&P BB).
- Risks and Contingencies:
- Legal: Management estimates reasonably possible future losses from existing legal proceedings could reach approximately $10 million.
- Investment Volatility: Net income is heavily influenced by unrealized gains/losses on marketable equity securities (including significant holdings in Berkshire Hathaway and Markel).
- Healthcare Valuation: Significant volatility in net income is driven by fair value adjustments to mandatorily redeemable noncontrolling interests in healthcare subsidiaries.
Investor Verification Checklist
- Non-GAAP Adjustments: Verify the impact of the $66.4 million non-cash interest expense related to the noncontrolling interest settlement on the bottom line.
- Investment Portfolio: Review the composition and unrealized gains of the $901.1 million marketable equity securities portfolio, which significantly impacts reported net income.
- Healthcare Segment: Assess the sustainability of the 36% revenue growth in Healthcare, driven by CSI Pharmacy expansion.
- Debt Covenants: Confirm compliance with financial covenants given the increase in total debt to $864.6 million.
- Share Repurchases: Note that recent share repurchases ($3.5 million) were primarily for tax withholding on vesting awards, not open market buybacks under the $500,000 share authorization.